Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology. The company develops APL-2 for intravitreal injection that is an injection into the eye, as well as subcutaneous injection, which is an injection into the tissue under the skin. It also develops APL-9 for intravenous administration in systemic indications, which is in single ascending dose Phase I clinical trial. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APLS
CUSIPN/A
Phone502-241-4114
Debt
Debt-to-Equity Ratio0.21
Current Ratio22.37
Quick Ratio22.37
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.96 per share
Price / Book7.42
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees39
Outstanding Shares55,940,000
Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions
What is Apellis Pharmaceuticals' stock symbol?
Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."
How were Apellis Pharmaceuticals' earnings last quarter?
Apellis Pharmaceuticals Inc (NASDAQ:APLS) issued its earnings results on Monday, April, 30th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.11. View Apellis Pharmaceuticals' Earnings History.
What price target have analysts set for APLS?
5 Wall Street analysts have issued 12-month target prices for Apellis Pharmaceuticals' stock. Their predictions range from $23.00 to $52.00. On average, they expect Apellis Pharmaceuticals' share price to reach $34.25 in the next twelve months. View Analyst Ratings for Apellis Pharmaceuticals.
What are Wall Street analysts saying about Apellis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Apellis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. " (6/18/2018)
- 2. Cantor Fitzgerald analysts commented, "We are initiating on Overweight rating and $52 price target. Apellis is in development of APL-2, a C3 complement inhibitor, for the treatment of complement-mediated diseases such as geographic atrophy (GA) and paroxysmal nocturnal hemoglobinuria (PNH), which are both entering Phase 3 development in 2H18. In our view, APL-2 has the potential to offer a first-in-class treatment for GA, a late stage dry form of AMD, and first-line therapy for PNH, an ultra rare orphan blood disorder. In our view, the compelling Phase 2 programs behind APL-2 support a high potential for success for APL-2 to serve these multi- billion market opportunities." (5/23/2018)
Are investors shorting Apellis Pharmaceuticals?
Apellis Pharmaceuticals saw a decline in short interest during the month of May. As of May 31st, there was short interest totalling 1,354,719 shares, a decline of 27.3% from the May 15th total of 1,862,741 shares. Based on an average daily trading volume, of 337,265 shares, the short-interest ratio is currently 4.0 days. Approximately 4.4% of the company's stock are sold short. View Apellis Pharmaceuticals' Current Options Chain.
Who are some of Apellis Pharmaceuticals' key competitors?
Some companies that are related to Apellis Pharmaceuticals include United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), Ultragenyx Pharmaceutical (RARE), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH), Array Biopharma (ARRY), HUTCHISON CHINA/S (HCM), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Supernus Pharmaceuticals (SUPN), Horizon Pharma (HZNP), Portola Pharmaceuticals (PTLA) and Ironwood Pharmaceuticals (IRWD).
Who are Apellis Pharmaceuticals' key executives?
Apellis Pharmaceuticals' management team includes the folowing people:
- Dr. Cedric Francois M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 46)
- Dr. Pascal Deschatelets Ph.D., Co-Founder & COO (Age 48)
- Mr. David O. Watson Esq., J.D., Gen. Counsel & VP of Corp. Devel. (Age 45)
- Dr. Federico Grossi M.D., Ph.D., Co-Founder & Sr. VP of Clinical Devel. (Age 44)
- Mr. Alec Machiels J.D., MBA, Co-Founder & Director (Age 45)
When did Apellis Pharmaceuticals IPO?
(APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.
When did Apellis Pharmaceuticals' lock-up period expire?
Apellis Pharmaceuticals' lock-up period expired on Tuesday, May 8th. Apellis Pharmaceuticals had issued 10,714,000 shares in its IPO on November 9th. The total size of the offering was $149,996,000 based on an initial share price of $14.00. Since the expiration of Apellis Pharmaceuticals' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.
Has Apellis Pharmaceuticals been receiving favorable news coverage?
Media coverage about APLS stock has trended somewhat positive recently, according to Accern Sentiment. The research firm scores the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Apellis Pharmaceuticals earned a media sentiment score of 0.24 on Accern's scale. They also gave news coverage about the company an impact score of 46.20 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Apellis Pharmaceuticals' major shareholders?
Apellis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.98%), Sofinnova Ventures Inc (1.63%), Victory Capital Management Inc. (0.67%), Candriam Luxembourg S.C.A. (0.22%), Northern Trust Corp (0.21%) and Russell Investments Group Ltd. (0.09%). Company insiders that own Apellis Pharmaceuticals stock include Global Strategic Fund I Venbio and Lukas Scheibler. View Institutional Ownership Trends for Apellis Pharmaceuticals.
Which institutional investors are buying Apellis Pharmaceuticals stock?
APLS stock was acquired by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Victory Capital Management Inc., BlackRock Inc., Russell Investments Group Ltd., New York State Common Retirement Fund, Rhumbline Advisers, Candriam Luxembourg S.C.A. and MetLife Investment Advisors LLC. Company insiders that have bought Apellis Pharmaceuticals stock in the last two years include Global Strategic Fund I Venbio and Lukas Scheibler. View Insider Buying and Selling for Apellis Pharmaceuticals.
How do I buy shares of Apellis Pharmaceuticals?
Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Apellis Pharmaceuticals' stock price today?
One share of APLS stock can currently be purchased for approximately $21.95.
How big of a company is Apellis Pharmaceuticals?
Apellis Pharmaceuticals has a market capitalization of $1.33 billion. The company earns $-51,000,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Apellis Pharmaceuticals employs 39 workers across the globe.
How can I contact Apellis Pharmaceuticals?
Apellis Pharmaceuticals' mailing address is 6400 WESTWIND WAY SUITE A, CRESTWOOD KY, 40014. The company can be reached via phone at 502-241-4114 or via email at [email protected]
MarketBeat Community Rating for Apellis Pharmaceuticals (APLS)
MarketBeat's community ratings are surveys of what our community members think about Apellis Pharmaceuticals and other stocks. Vote "Outperform" if you believe APLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
